Bio-Rad Laboratories Inc. (BIO)
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?
BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock
Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Bio-Rad Laboratories Q2 Earnings Call Highlights
Bio-Rad Laboratories NYSE: BIO reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral basis, as continued softness in academic research markets weighed on its Life Science segment.
Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript
Bio-Rad Laboratories (BIO) Beats Q2 Earnings Estimates
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.34 per share. This compares to earnings of $2.61 per share a year ago.
Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential
I assign a "Buy" rating to Bio-Rad Laboratories, citing activist involvement. Elliott's entry signals meaningful re-rating potential, assuming further operational improvements; BIO is already shifting M&A focus to revenue-generating bolt-ons and rationalizing R&D spend. The potential monetization of BIO's Sartorius stake, worth over $5 billion, appears more likely with Elliott's involvement, since the activist is also a shareholder of Sartorius.
Bio-Rad Laboratories, Inc. (BIO) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Elliott builds big stake in life-science tools supplier Bio-Rad Labs, WSJ reports
Activist investor Elliott Investment Management has built a sizeable stake in U.S. diagnostics supplier Bio-Rad Laboratories , and plans to push the company to boost its underperforming stock price, the Wall Street Journal reported on Sunday.
Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad
Elliott also has a stake in German lab-equipment supplier Sartorius, where Bio-Rad is also an investor.
Unlocking Bio-Rad (BIO) International Revenues: Trends, Surprises, and Prospects
Explore how Bio-Rad's (BIO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Bio-Rad Laboratories, Inc. (BIO) Q1 2026 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (BIO) Q1 2026 Earnings Call Transcript
